This year’s ELRIG Drug Discovery event, which took place at the ACC in Liverpool, was intended as a celebration of the sector, uniting scientists, academics and industry professionals towards the common goal of improving human health.

As such the theme for Drug Discovery 2025 was “A Festival of Life Science” with the conference offering over 150 talks across 14 scientific tracks and featured over 200 exhibitors.

Key topics featured at the conference included advances in robotics and automation, advanced models for drug discovery, hit-finding approaches in neurodegenerative disease therapeutics, chemical biology and omics, translating ideas into therapies, as well as sustainable drug development.

Some standout highlights of the show came from keynote speakers, Professor Heather Pinkett from Northwestern University and Dr Dafydd Owen from Pfizer Medicine Design, who spoke on day one and two respectively.

Professor Pinkett discussed how the fight against antimicrobial resistance (AMR) can be benefitted by the use structural prediction and computational strategies with a particular focus on ABC transporters.

On day two, Dr Owen gave a retrospective summary of the discovery of PAXLOVID during the Coronavirus pandemic, sharing the science behind the therapy’s discovery during a particularly challenging time.

Another interesting session came on day one with a track that discussed sustainable practices in drug discovery. Chaired by Anthony Holmes, NC3Rs, and Aurélie Thomas from AstraZeneca, the session explored how advanced cell and in silico models have the potential to reduce the industry’s reliance on animal testing, improving sustainability but also delivering human-relevant data for better translation success.

On day two, the “From concept to clinic: Accelerating the path to life-changing therapies” track was especially useful for those wanting to understand more about navigating the pharmaceutical market’s various strategies for business. The session, which was chaired by Hitesh Sanganee from Future Bio Consulting and Rupa Shree Appa-Pind from Novo Nordisk, saw talks discussing how companies secured funding, resources, and feasibility to help bring therapies to market. A panel discussion at the end provided a more conversational end to track detailing how innovative concepts were through to market in the face of challenges.